Investor Relations

AMS at a Glance

Advanced Medical Solutions Group plc is a leading developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced woundcare markets.

Our primary focus is to create quality outcomes for our:

  • Customers
  • Patients
  • Shareholders

Financial Calendar

Full Year Period End

31 December 2019

Interim Dividend Payment

25 October 2019

Interim Results Announcement

11 September 2019

Half Year Period End

30 June 2019

Final Dividend Payment

14 June 2019

Annual General Meeting

5 June 2019

Preliminary Results Announcement

13 March 2019
View Full Calendar

Financial Reports

2019 Interim Report

September 2019

2018 Interim Report

September 2018

2017 Interim Report

September 2017

2016 Interim Report

September 2016

2015 Interim Report

October 2015

2014 Interim Report

September 2014
View All Reports


Stifel UK Healthcare Seminar

AMS will attend the Stifel UK Healthcare Seminar on 5 December 2019. Read More

Acquisition of Biomatlante

Advanced Medical Solutions Group plc today announces it has acquired French company Biomatlante SA (“Biomatlante”), a well-established international developer and manufacturer... Read More

View More News

Latest Financial Highlights


This has been another period of growth for the Group despite the downturn in US LiquiBand® sales. Revenue increased by 2% to £48.7 million and by 1% at constant currency with continued good results from the majority of our geographies and product ranges. Excluding US LiquiBand®, Group sales increased by 10% on both a reported and constant currency basis.

Surgical revenues were impacted by a shortfall in US LiquiBand® sales and  decreased by 3% (4% at constant currency) to £26.5 million (2018 H1: £27.3 million). In contrast, Woundcare revenues increased by 9% (8% at constant currency) to £22.2 million (2018 H1: £20.3 million) as a result of increased partner demand for antimicrobial dressings in Infection Management.

At the start of 2019, we made some adjustments to our Business Unit structure to better manage our different surgical and advanced woundcare opportunities and to optimise the Group’s routes to market. We are pleased this is having the desired effect on woundcare and we believe that with our two individual business units we are now optimally positioned to drive growth for the future

Despite the challenging conditions experienced across our sector, we are pleased that the Group continues to see significant growth opportunities in our surgical and woundcare ranges. Whilst a slow-down in our progress with US LiquiBand® affected our overall Surgical growth during the period, the performance of our range in all other key markets and regions continues to be very strong.

In January 2019, AMS announced the acquisition of Sealantis for US$25 million. Sealantis’ products, which reduce leakage of blood or fluid in high-risk surgery, provide AMS with access to the growing $1 billion internal sealants market. Integration is progressing well and is largely complete. We expect to start clinical trials on target at around the end of 2019 to support first product launches for gastrointestinal surgery in 2021 with further innovations to follow in subsequent years.